Trending...
- New Townhome Building Released at Heritage at South Brunswick, Offering Private Perimeter Setting and Water Views - 162
- Comics Veteran on Return of Teenage Mutant Ninja Turtles Characters, 3-D Projects, Collaboration with Original 'Star Wars' Toy Engineer - 114
- Koko Lists Launches a New Way to Find "The Best" — Ranked by Real People, Not Stale Algorithms
NEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ: ANIK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Anika and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 30, 2025, Anika issued a press release "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."
More on Nyenta.com
On this news, Anika's stock price fell $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether Anika and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 30, 2025, Anika issued a press release "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."
More on Nyenta.com
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
- Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million
- WHAT: Dementia Caregivers to Meet with Congressional Candidate Chris Gallant
- Fisherman Never Lies Launches an Online Store for People Who Don't Trust a Word Their Fisherman Says
On this news, Anika's stock price fell $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
- ChargeOn Announces Conversational Payment Management Solution
- Theologian and bestselling author Apostle Tonya announces the release of her 21st book
- Worksploring Lab Gives Companies a Direct Line to the Future Workforce
- King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
- New Children's Book Celebrates Kindness, Courage and the Power of Following Your Dreams
- Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center
- Turn One Studio Named Finalist in HIA-LI's 2026 Long Island Business Distinction Awards
- Howling on Paper, Singer-Songwriter Steven Alvarado's First Book, Is Out Now
- Redefining Proactive Care: The Rise of the Hybrid Concierge Medical Model
- As Canada and America Turn on Each Other, These Two Authors Stay On Speaking Terms
- GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration
- Brévant Guide Launches New National Restaurant Guide Across Canada
- Casa Carlini to Launch "100 Books. 100 New Yorkers." in Spring 2027
- Klixsor Launches Self-Hosted Ad Tracker With Sub-Millisecond Redirects and Bot Protection
- Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not
- Emotely Launches Digital Gifting Built Around Feelings Rather Than Occasions
- Boom•Clap Introduces Cruise, a Managed Service for Contextual Awareness and Presence
- Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing
- VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8